Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced the Company's CEO, Dr. Lynn Kirkpatrick will be participating in ‘Strategies for Achieving Regulatory Milestones Faster: An Ensysce Biosciences & Quotient Sciences Customer Case Study Demonstrating the Benefits of an Integrated Approach for Accelerating Development' today, April 19 2023, at 11:30am ET as a featured speaker.
Ensysce Biosciences' PF614-MPAR is a novel opioid combination product for the potential treatment of chronic pain that is designed to prevent both abuse and overdose. It is currently in clinical trials using Quotient Sciences integrated formulation, manufacturing and Phase I clinical units.
Dr. Kirkpatrick will speak about how MPAR may impact future pain treatment or other target diseases and will highlight the reasons Ensysce selected Quotient Sciences as their development partner.
https://finance.yahoo.com/news/ensysce-ceo-dr-lynn-kirkpatrick-132500135.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.